Occuity, a rapidly growing Reading based MedTech company, are opening a new funding round to provide the company with the capital necessary to advance its handheld, non-contact screening and monitoring products and capitalise on a very attractive new opportunity.
Having previously become the largest MedTech raise on leading crowdfunding platform, Seedrs, the company has progressed both its first device, the PM1 Pachymeter, used to support the detection of glaucoma, and its GM1 Glucose meter for diabetes.
Alongside the filing of several new patents, these innovations have significantly improved the technology platform and enabled the engineering team to combine technical elements from both the PM1 and GM1 projects to unlock a new opportunity to create a handheld, non-contact meter that can measure the ‘Axial Length’ of the eye in just a few seconds.
Axial length is the key measurement required for myopia management in children – and with 4.76 billion people predicted to suffer from myopia by 2050, Myopia Management is probably the fastest growing market in the global Ophthalmic sector today.
Such is the size of the opportunity, and with interest in the market growing, Occuity has moved to rapidly develop a handheld prototype and successfully demonstrated its performance against existing larger, much more expensive desktop meters.
The AX1 Axiometer is set to revolutionise the way this key measurement is made.
Importantly, Occuity are in discussions with several of the leading myopia management suppliers in this multi-billion-dollar market. Occuity are confident that a partnership agreement will be agreed with one or more of these global corporations by the end of 2022.
In response to the new announcement, Dan Daly, CEO and Co-founder of Occuity said:
“Occuity continues to project sustained revenue growth and believes that the combination of the PM1 coming to market, coupled with a potentially huge commercial pipeline for the AX1, means that the company anticipates a significant valuation increase once these events are realised”.
As in the previous round, Occuity additionally plans to offer its community of friends and followers the opportunity to invest in the business by providing a crowdfunding element to the round via Seedrs. More details on this will be announced in due course.
Occuity will be hosting a number of investment focused webinars with Q&A sessions and will be providing an opportunity for those interested in investing to join the team for a technology showcase day at its Reading headquarters. More details and links can be found below.
For More Information Contact:
Head of Digital Marketing
Tel: 01183 500 800
Radar Healthcare announces Aamal Medical partnership
Photodisinfectant: can light curb the antimicrobial resistance crisis?
Video games may help teens discuss mental health
Why it’s time to revisit workplace mental health initiatives and make them work for everyone
Innovations in self-diagnostics technology: Paving the way to a healthier future?
Telehealth solution revolutionising stroke care in Cardiff and Vale UHB
‘I was producing addicts every week’ – the doctor-turned-tech leader taking on the opioid crisis
Novel cell therapy granted FDA approval for use as investigational new drug
Pathpoint eTrauma launches at Medway NHS Foundation Trust
New production method could make cheaper drug treatments possible
- Opinion3 weeks ago
We need to think differently about EPR deployments and redefine the pre-implementation approach
- News1 week ago
Choosing the right stem cell treatment centre
- Deals4 weeks ago
Greater Manchester Pathology Network works with Clinisys on an integrated, interoperable LIMS service
- Research3 weeks ago
AI algorithm developed to measure muscle development